Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
Anticoagulation is essential in patients with ST elevation myocardial infarction (STEMI) to prevent further thrombosis and to maintain patency of the infarct-related artery after reperfusion. The various anticoagulant medications available for use in patients with STEMI include unfractionated heparin (UFH), low-molecular-weight heparin, fondaparinux, and bivalirudin, a direct thrombin inhibitor. The authors review the current anticoagulation strategies for patients with STEMI undergoing primary percutaneous coronary intervention (PCI), fibrinolysis, or no reperfusion. The authors present the latest evidence and controversies on this topic, with a focus on bivalirudin versus UFH in the setting of primary PCI for STEMI.
Published In/Presented At
Shah, N., & Cox, D. (2016). Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. Interventional cardiology clinics, 5(4), 497–511. https://doi.org/10.1016/j.iccl.2016.06.008
Medicine and Health Sciences
Department of Medicine, Cardiology Division